

Claims

1. A compound that is 3-ethyl-5-methyl-1-((5-(2,4,5-trifluoro-3-hydroxyphenyl)-1,3,4-thiadiazol-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione



, or a pharmaceutically acceptable salt thereof.

2. The compound as claimed in claim 1, that is 3-ethyl-5-methyl-1-((5-(2,4,5-trifluoro-3-hydroxyphenyl)-1,3,4-thiadiazol-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione



.

3. A pharmaceutical composition comprising a compound that is 3-ethyl-5-methyl-1-((5-(2,4,5-trifluoro-3-hydroxyphenyl)-1,3,4-thiadiazol-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione, or a pharmaceutically acceptable salt thereof, as claimed in claim 1, and a pharmaceutically acceptable excipient.

4. The pharmaceutical composition as claimed in claim 3, wherein the compound is 3-ethyl-5-methyl-1-((5-(2,4,5-trifluoro-3-hydroxyphenyl)-1,3,4-thiadiazol-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione.

5. A compound that is 3-ethyl-5-methyl-1-((5-(2,4,5-trifluoro-3-hydroxyphenyl)-1,3,4-thiadiazol-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione, or a pharmaceutically acceptable salt thereof, as claimed in claim 1 or claim 2, or a pharmaceutical composition as claimed in claim 3 or claim 4, for use in therapy.

6. Use of a compound that is 3-ethyl-5-methyl-1-((5-(2,4,5-trifluoro-3-hydroxyphenyl)-1,3,4-thiadiazol-2-yl)methyl)pyrimidine-2,4(1H,3H)-dione, or a pharmaceutically acceptable salt thereof, as claimed in claim 1 or claim 2, in the manufacture of a medicament for the treatment of liver disease.

7. The use according to claim 6, wherein the liver disease is selected from alcoholic liver disease, non-alcoholic liver disease, NAFLD, NASH, liver fibrosis, cirrhosis, isolated steatosis, liver inflammation, alcoholic steatohepatitis (ASH), hepatitis C virus (HCV) and hepatocellular carcinoma (HCC).

8. The use according to claim 6, wherein the liver disease is liver fibrosis.

9. The use according to claim 6, wherein the liver disease is cirrhosis.